Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults
Purpose of Review
Migraines are prevalent and cause significant morbidity, decline in quality of life and healthcare costs universally. Treatment options are varied, but efficacy is limited. This review centers on Eptinezumab-jjmr, a humanized monoclonal specific to CGRP for the prevention of migraines in adults. Herein presented are the science and mechanism of action, indication and clinical evidence for use.
Recent Findings
Migraines are severe, recurrent headaches, which are either episodic or chronic in nature. The pain is severe, often accompanied by co-morbid symptoms, such as photophobia, phonophobia, nausea and emesis, and is limiting in nature. It is a prevalent disorder that causes significant, worldwide disability, morbidity, suffering, and costs.
The pathophysiology of migraines is actively studied, though recent research points to an initiating event causing migraine generation, that is then propagated by other brain regions, a significant one being the trigeminocervical complex. This is driven by biochemical transmitters, chiefly CGRP. This discovery led to the development of CGRP-targeting drugs, including gepants (small molecular antagonists) and anti-CGRP antibodies, such as Eptinezumab-jjmr.
Traditional therapy includes preventative and abortive treatment; however, adherence with preventative treatment has been historically poor, and certain types of abortive therapy carry risks and side effects that preclude them from a large patient population. Moreover, traditional therapy often falls short in migraine therapy. CGRP antagonist, including Eptinezumab, aims to cover the gaps in migraine therapy. We present here evidence to support the safe and effective use of Eptinezumab for the prevention of migraines.
Summary
Migraines are a prevalent primary headache disorder causing significant morbidity worldwide. Traditional abortive and preventative treatments fall short for many patients. Eptinezumab is part of new generation of CGRP-targeting medications and has shown significant evidence to support its use for the prevention of migraines. Further research is required to properly compare eptinezumab with existing pharmacotherapy and update guidelines on the appropriate combinations of therapies that are not available and the correct patient selection for each.
1. Peters GL. Migraine overview and summary of current and emerging treatment options. The American journal of managed care. Published online 2019.
2. MacGregor EA. Migraine. Ann Intern Med. 2017;166(7):ITC49. doi:10.7326/aitc201704040
3. Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurologic Clinics. 2019;37(4):631-649. doi:10.1016/j.ncl.2019.06.001
4. Stovner LJ, Nichols E, Steiner TJ, et al. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 2018;17(11):954-976. doi:10.1016/s1474-4422(18)30322-3
5. Adams AM, Serrano D, Buse DC, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35(7):563-578. doi:10.1177/0333102414552532
6. May A, Schulte LH. Chronic migraine: Risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12(8):455-464. doi:10.1038/nrneurol.2016.93
7. Cameron C, Kelly S, Hsieh SC, et al. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015;55(S4):221-235. doi:10.1111/head.12601
8. Urits I, Clark G, An D, et al. An Evidence-Based Review of Fremanezumab for the Treatment of Migraine. Pain Ther. 2020;9(1):195-215. doi:10.1007/s40122-020-00159-3
9. Urits I, Yilmaz M, Charipova K, et al. An Evidence-Based Review of Galcanezumab for the Treatment of Migraine. Neurol Ther. 2020;9(2):403-417. doi:10.1007/s40120-020-00214-3
10. Urits I, Jones MR, Gress K, et al. CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review. Curr Pain Headache Rep. 2019;23(5). doi:10.1007/s11916-019-0768-y
11. Scuteri D, Corasaniti MT, Tonin P, Bagetta G. Eptinezumab for the treatment of migraine. Drugs Today. 2019;55(11):695-703. doi:10.1358/dot.2019.55.11.3069864
12. Dodick DW, Lipton RB, Silberstein S, et al. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia. 2019;39(9):1075-1085. doi:10.1177/0333102419858355
13. Rizzoli P, Mullally WJ. Headache. American Journal of Medicine. 2018;131(1):17-24. doi:10.1016/j.amjmed.2017.09.005
14. Dowson A. The burden of headache: global and regional prevalence of headache and its impact. Int J Clin Pract. 2015;69:3-7. doi:10.1111/ijcp.12650
15. Burch RC, Loder S, Loder E, Smitherman TA. The Prevalence and Burden of Migraine and Severe Headache in the United States: Updated Statistics From Government Health Surveillance Studies. Headache: The Journal of Head and Face Pain. 2015;55(1):21-34. doi:10.1111/head.12482
16. Yeh WZ, Blizzard L, Taylor BV. What is the actual prevalence of migraine? Brain Behav. 2018;8(6):e00950. doi:10.1002/brb3.950
17. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of Migraine Headache in the United States: Relation to Age, Income, Race, and Other Sociodemographic Factors. JAMA. 1992;267(1):64-69. doi:10.1001/jama.1992.03480010072027
18. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646-657. doi:10.1046/j.1526-4610.2001.041007646.x
19. Puledda F, Messina R, Goadsby PJ. An update on migraine: current understanding and future directions. J Neurol. 2017;264(9):2031-2039. doi:10.1007/s00415-017-8434-y
20. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: A disorder of sensory processing. Physiological Reviews. 2017;97(2):553-622. doi:10.1152/physrev.00034.2015
21. Charles A. The pathophysiology of migraine: implications for clinical management. The Lancet Neurology. 2018;17(2):174-182. doi:10.1016/s1474-4422(17)30435-0
22. Dodick DW. Migraine. The Lancet. 2018;391(10127):1315-1330. doi:10.1016/s0140-6736(18)30478-1
23. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011;12(10):570-584. doi:10.1038/nrn3057
24. Lassen L, Haderslev P, Jacobsen V, Iversen H, Sperling B, Olesen J. CGRP May Play A Causative Role in Migraine. Cephalalgia. 2002;22(1):54-61. doi:10.1046/j.1468-2982.2002.00310.x
25. Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179-1186. doi:10.1177/0333102410368444
26. Burstein R, Noseda R, Borsook D. Migraine: Multiple processes, complex pathophysiology. Journal of Neuroscience. 2015;35(17):6619-6629. doi:10.1523/jneurosci.0373-15.2015
27. Peroutka SJ. What Turns on a Migraine? A Systematic Review of Migraine Precipitating Factors. Curr Pain Headache Rep. 2014;18(10):453-458. doi:10.1007/s11916-014-0454-z
28. Todd C, Lagman-Bartolome AM, Lay C. Women and Migraine: the Role of Hormones. Curr Neurol Neurosci Rep. 2018;18(7). doi:10.1007/s11910-018-0845-3
29. Ashina S, Serrano D, Lipton RB, et al. Depression and risk of transformation of episodic to chronic migraine. J Headache Pain. 2012;13(8):615-624. doi:10.1007/s10194-012-0479-9
30. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache. 2008;48(8):1157-1168. doi:10.1111/j.1526-4610.2008.01217.x
31. Bigal ME, Lipton RB. Modifiable Risk Factors for Migraine Progression. Headache: The Journal of Head and Face Pain. 2006;46(9):1334-1343. doi:10.1111/j.1526-4610.2006.00577.x
32. Tinsley A, Rothrock JF. What Are We Missing in the Diagnostic Criteria for Migraine? Curr Pain Headache Rep. 2018;22(12). doi:10.1007/s11916-018-0733-1
33. Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16(1):86-92. doi:10.1007/s11916-011-0233-z
34. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American migraine prevalence and prevention study. Headache. 2007;47(3):355-363. doi:10.1111/j.1526-4610.2006.00631.x
35. American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2018;59(1):1-18. doi:10.1111/head.13456
36. Silberstein SD, Lipton RB. Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention. Headache. 2015;55:99-102. doi:10.1111/head.12505
37. Ong JJY, Wei DYT, Goadsby PJ. Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. Drugs. 2018;78(4):411-437. doi:10.1007/s40265-018-0865-y
38. Mallick-Searle T, Moriarty M. Unmet needs in the acute treatment of migraine attacks and the emerging role of calcitonin gene-related peptide receptor antagonists. J Am Assoc Nurse Pract. 2020;33(6):419-428. doi:10.1097/jxx.0000000000000397
39. Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. SpringerPlus. 2016;5(1):1-14. doi:10.1186/s40064-016-2211-8
40. Mallick-Searle T, Moriarty M. Unmet needs in the acute treatment of migraine attacks and the emerging role of calcitonin gene-related peptide receptor antagonists. J Am Assoc Nurse Pract. 2020;33(6):419-428. doi:10.1097/jxx.0000000000000397
41. Agostoni EC, Barbanti P, Calabresi P, et al. Current and emerging evidence-based treatment options in chronic migraine: A narrative review. J Headache Pain. 2019;20(1). doi:10.1186/s10194-019-1038-4
42. Peck J, Urits I, Zeien J, et al. A Comprehensive Review of Over-the-counter Treatment for Chronic Migraine Headaches. Curr Pain Headache Rep. 2020;24(5):1-9. doi:10.1007/s11916-020-00852-0
43. Dodick DW. Migraine. The Lancet. 2018;391(10127):1315-1330. doi:10.1016/s0140-6736(18)30478-1
44. Lupi C, Benemei S, Guerzoni S, Pellesi L, Negro A. Pharmacokinetics and pharmacodynamics of new acute treatments for migraine. Expert Opinion on Drug Metabolism and Toxicology. 2019;15(3):189-198. doi:10.1080/17425255.2019.1578749
45. de Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacology and Therapeutics. 2020;211:1-10. doi:10.1016/j.pharmthera.2020.107528
46. Digre KB. What's New in the Treatment of Migraine? Journal of Neuro-Ophthalmology. 2019;39(3):352-359. doi:10.1097/wno.0000000000000837
47. Rapoport AM, Freitag F, Pearlman SH. Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs. 2010;24(11):929-940. doi:10.2165/11317540-000000000-00000
48. Lipton RB, Munjal S, Brand-Schieber E, Rapoport AM. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study. Headache. 2018;58(5):676-687. doi:10.1111/head.13309
49. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633-658. doi:10.1046/j.1468-2982.2002.00404.x
50. Ceriani CEJ, Wilhour DA, Silberstein SD. Novel Medications for the Treatment of Migraine. Headache. 2019;59(9):1597-1608. doi:10.1111/head.13661
51. Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015;79(6):886-895. doi:10.1111/bcp.12591
52. Naegel S, Obermann M. Topiramate in the prevention and treatment of migraine: Efficacy, safety and patient preference. Neuropsychiatric Disease and Treatment. 2010;6(1):17-28. doi:10.2147/ndt.s6459
53. White HS. Molecular pharmacology of topiramate: Managing seizures and preventing migraine. Headache. 2005;45(s1):S48-S56. doi:10.1111/j.1526-4610.2005.4501006.x
54. de Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacology and Therapeutics. 2020;211:107528. doi:10.1016/j.pharmthera.2020.107528
55. Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opinion on Investigational Drugs. 2019;28(6):555-567. doi:10.1080/13543784.2019.1618830
56. Edinoff AN, Casey CA, Colon MA, et al. Ubrogepant to Treat Acute Migraine in Adults. Neurology International. 2021;13(1):32-45. doi:10.3390/neurolint13010004
57. Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: New drugs, new hope? J Headache Pain. 2019;20(1):1-13. doi:10.1186/s10194-019-0974-3
58. Raffaelli B, Neeb L, Reuter U. Monoclonal antibodies for the prevention of migraine. Expert Opinion on Biological Therapy. 2019;19(12):1307-1317. doi:10.1080/14712598.2019.1671350
59. Xu D, Chen D, Zhu LN, et al. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials. Cephalalgia. 2019;39(9):1164-1179. doi:10.1177/0333102419829007
60. de Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacology & Therapeutics. 2020;211:1-13. doi:10.1016/j.pharmthera.2020.107528
61. Urits I, Patel M, Putz ME, et al. Acupuncture and Its Role in the Treatment of Migraine Headaches. Neurol Ther. 2020;9(2):375-394. doi:10.1007/s40120-020-00216-1
62. Berger A, Hasoon J. Sphenopalatine ganglion block for abortive treatment of a migraine headache. Saudi J Anaesth. 2020;14(4):548. doi:10.4103/sja.sja_810_19
63. J H, A B. Chronic Post Traumatic Headaches Unresponsive to Medication Management. Asp Biomed Clin Case Rep. 2020;3(2):114-115. doi:10.36502/2020/asjbccr.6196
64. Dhillon S. Eptinezumab: First Approval. Drugs. 2020;80(7):733-739. doi:10.1007/s40265-020-01300-4
65. LLC LP. VYEPTI-eptinezumab-jjmr injection Prescribing Information.
66. Vice E. Lundbeck's VYEPTI™ eptinezumab-jjmr, Quarterly Treatment for Migraine Prevention in Adults, Now Available in. Published online 2020:3-4.
67. Lundbeck announces European Medicines Agency acceptance of marketing authorization application for eptinezumab for the prevention of migraine | H.Lundbeck A/S. Accessed January 17, 2021. https://investor.lundbeck.com/news-releases/news-release-details/lundbeck-announces-european-medicines-agency-acceptance
68. Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1). doi:10.1186/s10194-018-0955-y
69. Raffaelli B, Reuter U. The biology of monoclonal antibodies: Focus on calcitonin gene-related peptide for prophylactic migraine therapy. Neurotherapeutics. 2018;15(2):324-335. doi:10.1007/s13311-018-0622-7
70. Taylor FR. CGRP, Amylin, Immunology, and Headache Medicine. Headache. 2019;59(1):131-150. doi:10.1111/head.13432
71. Yeh JF, Akinci A, Al Shaker M, et al. Monoclonal antibodies for chronic pain: A practical review of mechanisms and clinical applications. Mol Pain. 2017;13:174480691774023. doi:10.1177/1744806917740233
72. Vollesen ALH, Snoer A, Beske RP, et al. Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks: A Randomized Clinical Trial. JAMA Neurol. 2018;75(10):1187-1197. doi:10.1001/jamaneurol.2018.1675
73. Scuteri D, Adornetto A, Rombolà L, et al. New trends in migraine pharmacology: Targeting calcitonin gene-related peptide (CGRP) with monoclonal antibodies. Front Pharmacol. 2019;10(APR). doi:10.3389/fphar.2019.00363
74. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338-350. doi:10.1038/s41582-018-0003-1
75. Edvinsson L. The CGRP Pathway in Migraine as a Viable Target for Therapies. Headache. 2018;58:33-47. doi:10.1111/head.13305
76. Garcia-Martinez LF, Raport CJ, Ojala EW, et al. Pharmacologic Characterization of ALD403, a Potent Neutralizing Humanized Monoclonal Antibody Against the Calcitonin Gene-Related Peptide. J Pharmacol Exp Ther. 2020;374(1):93-103. doi:10.1124/jpet.119.264671
77. Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs - Lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12(12):1-22. doi:10.3390/pharmaceutics12121180
78. Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of epinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365-e1377. doi:10.1212/wnl.0000000000009169
79. Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. The Lancet. 2018;392(10161):2280-2287. doi:10.1016/s0140-6736(18)32534-0
80. Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: A randomised, double-blind, placebo-controlled, exploratory phase 2 trial. The Lancet Neurology. 2014;13(11):1100-1107. doi:10.1016/s1474-4422(14)70209-1
81. Dodick DW, Lipton RB, Silberstein S, et al. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia. 2019;39(9):1075-1085. doi:10.1177/0333102419858355
82. Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241-254. doi:10.1177/0333102420905132
83. Saper J, Lipton R, Kudrow D, et al. Primary Results of PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Trial: a Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for Prevention of Frequent Epis. Neurology. 2018;90(15 Supplement):S20.001.
84. Tepper SJ. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Headache. 2018;58:276-290. doi:10.1111/head.13417
85. Baker B, Schaeffler B, Beliveau M, et al. Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol Res Perspect. 2020;8(2):e00567. doi:10.1002/prp2.567
86. Silberstein S, Diamond M, Hindiyeh NA, et al. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain. 2020;21(1):120. doi:10.1186/s10194-020-01186-3
87. Shin HE, Park JW, Kim YI, Lee KS. Headache impact test-6 (HIT-6) scores for migraine patients: Their relation to disability as measured from a headache diary. J Clin Neurol (Korea). 2008;4(4):158-163. doi:10.3988/jcn.2008.4.4.158
88. Eptinezumab (Vyepti) for migraine prevention. The Medical letter on drugs and therapeutics. 2020;62(1599):85-87.
89. Bucklan J, Ahmed Z. CGRP antagonists for decreasing migraine frequency: New options, long overdue. Cleveland Clinic Journal of Medicine. 2020;87(4):211-218. doi:10.3949/ccjm.87a.19048
90. American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019;59(1):1-18. doi:10.1111/head.13456
91. Ibekwe A, Perras C, Mierzwinski-Urban M. Monoclonal Antibodies to Prevent Migraine Headaches. Published online 2016.
92.Mitsikostas DD, Reuter U. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: Comparisons across randomized controlled studies. Current Opinion in Neurology. 2017;30(3):272-280. doi:10.1097/WCO.0000000000000000438
93. Silberstein S, Diamond M, Hindiyeh NA, et al. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain. 2020;21(1):120. doi:10.1186/s10194-020-01186-3
94. Dodick DW, Lipton RB, Silberstein S, et al. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia. 2019;39(9):1075-1085. doi:10.1177/0333102419858355
95. Saper J, Lipton R, Kudrow D, et al. Primary Results of PROMISE-1 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Trial: a Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab for Prevention of Frequent Epis. Neurology. 2018;90(15 Supplement):S20.001.